SCCI Active Clinical Trials

The SimmonsCooper Cancer Institute administers a number of clinical trials and offers to our patients more than 130 national trials in cancer treatment and control through a variety of clinical trial programs.  More clinical trials are being added as the cancer care teams develop and expand. 

Information about cancer trials is at http://www.siumed.edu/cancer/researchpages/trials.html.  Visitors to the Web site can contact the study coordinator by phone about possible participation.  Patients also can call the clinical trials coordinator at 217-545-1946 weekdays.

●    Phase II biomarker trial of gelatin encapsulated extract of American ginseng root (LEAG) in breast cancer.
●    Phase II BIBW2992 versus Cetuximab (Erbitux) in patients with metastatic or recurrent head and neck squamous cell cancer.
●    Phase II study of dasatinib in previously-treated patients with metastatic colorectal cancer.
●    Phase II study of Bay 43-9006 for patients with Imatinib and sunitinib resistant GIST.                                             
●    Prospective study to assess the anatomical relationship of level 1B lymph nodes to the submandibular gland in patients with carcinoma of the upper aerodigestive tract.
●    Phase II study of RADPLAT and Tarceva in advanced head and neck squamous cell carcinoma.
●    Open label single arm trial of Zalutumumab, a human monoclonal anti-EGF receptor antibody in combination with best supportive care in patients with non-curable squamous cell carcinoma of the head and neck who have failed standard platinum-based chemotherapy.
●    Phase II study of Bay 43-9006 for relapsed chronic lymphocytic leukemia.
●    Phase II randomized study of Vorinostat or placebo in combination with Carboplatin and Paclitaxel for patients with advanced or metastatic non-small cell lung cancer.
●    Phase III study of Inotuzumab Ozogamicin (CMC-544) administered in combination with Rituximab compared to a defined investigator’s choice therapy in patients with relapsed or refractory, CD22-positive follicular B-cell non-Hodgkin’s lymphoma.
●    Phase II Epothilone B analog BMS-247550 in patients with relapsed aggressive non-Hodgkin’s lymphoma.
●    Phase II randomized study of GW786034 (Pazopanib) in stage D0 relapsed androgen sensitive prostate cancer following limited GnRh agonist therapy.
●    Effect of biofeedback on urinary control after treatment for prostate cancer.
●    Phase II study of Sunitinib in Iodine-131 refractory unresected differentiated thyroid cancers and medullary thyroid cancers.
●    Phase II randomized study comparing two dose schedules of Ezatiostat Hydrochloride (Telintra™, TLK199 tablets) in low to intermediate-1 risk myelodysplastic syndrome (MDS).

7/10/08